Modeling and simulation (M&S) is a scientific approach used in the drug development process. Biosimulation process is a computer-aided mathematical simulation of biological processes.
Biosimulation provides information regarding dose precision, interaction between drugs on a molecular level, as well as physiologically-based pharmacokinetic (PBPK) modelling using sophisticated pharmacodynamics models of the heart, liver, and other systems. Furthermore, according to the U.S. FDA’s Office of Clinical Pharmacology (OCP), 2014 data, PBPK modelling: a mathematical predictions of drug interactions with other drugs is increasingly used by FDA in drug discovery and early development process.
Get Sample Report with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-sample/2016
Global Biosimulation Market: Overview
The global biosimulation market size was valued at US$ 1,323.1 Mn in 2017 and is expected to exhibit a CAGR of 15.4% during the forecast period (2018 – 2026). Growing adoption of biosimulation tools in different stages of drug developments would boost the global biosimulation market in the near future.
Rising incidence of diseases, increasing demand for biosimilars owing to their cost-effectiveness, increasing research and development activities, and acquisition among key players are expected to drive the global biosimulation market.
Pharmaceutical companies, non-profit organizations, and others are investing in research and development activities. Moreover, major players are using biosimulation techniques for enhancing efficacy of drug discovery and development process, which is expected to drive growth of the biosimulation market. Moreover, several government are funding research organisations and businesses with grants to drive scientific research. For instance, Innovate UK, a U.K.-based research and innovative agency, provide businesses and research organizations with grants to drive scientific research. This agency supported two companies, Adorial Pharma Limited and C4X Discovery Holdings plc. for developing a novel mathematical-based system of drug discovery.
Purchase This Premium Report Here To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/2016
Moreover, rising prevalence of genetic diseases is expected to increase research and development funding in gene therapy and diagnosis of genetic disease, which is anticipated to increase the adoption of biosimulation products and services during the forecast period. For instance, according to the Research, Condition, and Disease Categories (RCDC) July 2017 report, National Institute of Health (NIH) had initiated funding in various disease categories through grants, contracts, and other funding mechanisms. NIH invested US$ 422 million, US$ 462 million, and US$ 486 million on gene therapy, genetic clinical trials, and genetic testing in 2015, 2016, and 2017, respectively.Global Biosimulation Market: Competitive Landscape
Key players operating in the global biosimulation market are LeadScope, Inc., L.P., Simulations Plus, Inc., Certara, Dassault Systèmes (Accelrys), Compugen Inc., Schrödinger, LLC, Chemical Computing Group ULC, In Silico Biosciences, Inc., Advanced Chemistry Development, Inc., Genedata AG, Physiomics PLC, and Pharmaceutical Product Development, LLC (Evidera).
Global Biosimulation Market: Opportunities
Major players in biosimulation market are focusing on strategies such as expansions of their product offerings through strategic acquisition. For instance, in December 2015, Certara, a biosimulation technology-enabled drug development company, acquired XenologiQ, a U.K.-based quantitative systems pharmacology (QSP) consultancy. Furthermore, in February 2018, Certara acquired BaseCase Management GmbH, a data visualization software as a service (SaaS) company. Through this acquisition, the company had strengthened its data visualization and communication capabilities.
Global Biosimulation Market: Key Trends
In July 2018, EndoMimyk, an endoscopy simulator, was designed by a team of scientists from Indian Institute of Science (IISc). This simulator combines haptic technology with advanced simulation and instrumented tools to offer high-fidelity, realistic, and immersive training in gastrointestinal and bronchoscopy procedures. In March 2017, Certara, a global leader in biosimulation, designed a new licensing approach especially for smaller organizations to access its physiologically-based pharmacokinetic (PBPK) modeling and simulation platform, Simcyp.
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/2016
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837